Anti phospho vegfr1 tyr1213

Immunoblotting experiments were performed as previously described.^{21 (link)} The antibodies used were: anti-sVEGFR1-i13 polyclonal antibody, generated against a peptide mapping in the unique C-terminus,^{14 (link)} anti-VEGFR2 (clone 55B11), anti-actin and anti-active caspase-3 from Cell signalling. Anti-tubulin was from Santa Cruz, anti-actin from Sigma-Aldrich, anti-phospho-VEGFR1-Tyr1213 from Millipore and anti-phospho-VEGFR2-Tyr1214 from Invitrogen. Antibody against total β1 integrin (serum 227) was kindly provided by Dr Albiges-Rizo (Institute For Advanced Biosciences, Grenoble). The other antibodies used for Proximity Ligation Assay and immunohistochemistry were: mouse anti-β1 integrin (4B7R) and anti-VEGFR2 (4B4) antibodies from ThermoFisher Scientific, rabbit anti-VEGFR2 from Sigma-Aldrich and anti-VEGFR1 (Santa Cruz).

Immunoblotting experiments were performed as previously described^{43 (link)}. The antibodies used were: anti-actin from Sigma, anti-tubulin (clone B512, sc-23948) from Santa Cruz, anti-SOX2 (AB5603) and anti-phospho-VEGFR1-Tyr1213 (cat#07-758) from Millipore and anti-SRSF2 (clone 4F-11) from Euromedex. The specific anti-sVEGFR1-i13 was generated against a peptide mapping in the unique C-terminus^{13 (link)}. We previously checked that this antibody recognizes sVEGFR1-i13 protein in our cells by using siRNA targeting retained intron 13 in sVEGFR1-i13^{4 (link)}. The anti-VEGF₁₆₅ antibody raised against the six terminal amino acids (CDKPRR sequence) and a sixteen amino acids sequence targeting terminal part of VEGF₁₆₅ encompassing exons 7 and 8a was produced by Covalab (Villeurbanne, France). We previously checked that this antibody recognizes a recombinant VEGF₁₆₅ but not VEGF₁₆₅b protein¹⁹ .